FCGR2B and neoplasm: In keeping with this, IgG1SDALIE mAb, with an optimized A:I (CD16:CD32b) binding profile, demonstrated superior anti-tumor activity relative to all evaluated chimeric anti-CTLA-4 Fc variants.